View in EDS HTML Full Text PDF Full Text

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Authors: Nuzzo PV; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Ravera F; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Internal Medicine, University of Genoa, Genova, Italy., Saieva C; Cancer Risk Factors and Lifestyle Epidemiology Unit-ISPRO, Florence, Italy., Zanardi E; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Fotia G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy., Malgeri A; Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy., Rossetti S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Valença LB; Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil.; Hospital Sao Rafael, Salvador, Brazil., Oliveira TM; Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil.; Hospital Sao Rafael, Salvador, Brazil., Vauchier C; Thoracic Oncology Unit, Bichat-Claude Bernard Hospital, Paris, France., Pereira Mestre R; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland., Modesti M; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland., Patrikidou A; Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France., Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Procopio G; Oncology Unit, ASST Cremona, Cremona, CR, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy., Russo A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Francini E; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence 50134, Italy.
Source: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 03; Vol. 15, pp. 17588359231156147. Date of Electronic Publication: 2023 Mar 03 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36895852
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Nuzzo+PV%22">Nuzzo PV</searchLink>; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ravera+F%22">Ravera F</searchLink>; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.; Department of Internal Medicine, University of Genoa, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Saieva+C%22">Saieva C</searchLink>; Cancer Risk Factors and Lifestyle Epidemiology Unit-ISPRO, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Zanardi+E%22">Zanardi E</searchLink>; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22Fotia+G%22">Fotia G</searchLink>; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.<br /><searchLink fieldCode="AU" term="%22Malgeri+A%22">Malgeri A</searchLink>; Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Rossetti+S%22">Rossetti S</searchLink>; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Valença+LB%22">Valença LB</searchLink>; Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil.; Hospital Sao Rafael, Salvador, Brazil.<br /><searchLink fieldCode="AU" term="%22Oliveira+TM%22">Oliveira TM</searchLink>; Instituto D'Or de Pesquisa e Ensino (IDOR), Salvador, Brazil.; Hospital Sao Rafael, Salvador, Brazil.<br /><searchLink fieldCode="AU" term="%22Vauchier+C%22">Vauchier C</searchLink>; Thoracic Oncology Unit, Bichat-Claude Bernard Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Pereira+Mestre+R%22">Pereira Mestre R</searchLink>; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.<br /><searchLink fieldCode="AU" term="%22Modesti+M%22">Modesti M</searchLink>; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.<br /><searchLink fieldCode="AU" term="%22Patrikidou+A%22">Patrikidou A</searchLink>; Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Pignata+S%22">Pignata S</searchLink>; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Procopio+G%22">Procopio G</searchLink>; Oncology Unit, ASST Cremona, Cremona, CR, Italy.<br /><searchLink fieldCode="AU" term="%22Fornarini+G%22">Fornarini G</searchLink>; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy.<br /><searchLink fieldCode="AU" term="%22De+Giorgi+U%22">De Giorgi U</searchLink>; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Russo+A%22">Russo A</searchLink>; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.<br /><searchLink fieldCode="AU" term="%22Francini+E%22">Francini E</searchLink>; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence 50134, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101510808%22">Therapeutic advances in medical oncology</searchLink> [Ther Adv Med Oncol] 2023 Mar 03; Vol. 15, pp. 17588359231156147. <i>Date of Electronic Publication: </i>2023 Mar 03 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage%22">Sage </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101510808 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1758-8340 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217588340%22">17588340 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Med Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36895852
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/17588359231156147
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 17588359231156147
    Titles:
      – TitleFull: Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Nuzzo PV
      – PersonEntity:
          Name:
            NameFull: Ravera F
      – PersonEntity:
          Name:
            NameFull: Saieva C
      – PersonEntity:
          Name:
            NameFull: Zanardi E
      – PersonEntity:
          Name:
            NameFull: Fotia G
      – PersonEntity:
          Name:
            NameFull: Malgeri A
      – PersonEntity:
          Name:
            NameFull: Rossetti S
      – PersonEntity:
          Name:
            NameFull: Valença LB
      – PersonEntity:
          Name:
            NameFull: Oliveira TM
      – PersonEntity:
          Name:
            NameFull: Vauchier C
      – PersonEntity:
          Name:
            NameFull: Pereira Mestre R
      – PersonEntity:
          Name:
            NameFull: Modesti M
      – PersonEntity:
          Name:
            NameFull: Patrikidou A
      – PersonEntity:
          Name:
            NameFull: Pignata S
      – PersonEntity:
          Name:
            NameFull: Procopio G
      – PersonEntity:
          Name:
            NameFull: Fornarini G
      – PersonEntity:
          Name:
            NameFull: De Giorgi U
      – PersonEntity:
          Name:
            NameFull: Russo A
      – PersonEntity:
          Name:
            NameFull: Francini E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 03
              Text: 2023 Mar 03
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 1758-8340
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Therapeutic advances in medical oncology
              Type: main
ResultId 1